Key facts
- It has raised $370.0M; the latest was Later Stage VC ($108.0M) in Dec 2025.
- Notable investors include HSG (Hong Kong), IDG Capital, Temasek Holdings, Boyu Capital, MPC (Beijing) — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for D3 Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for D3 Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About D3 Bio
Developer of biotechnology focused on the development and innovation of drugs in oncology and immunology. The company focuses on the discovery, development, and registration of new medicines in oncology and immunology, aiming to create novel and clinically meaningful new therapies for patients in need.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 2020
- Website
- d3bio.com/
- Ownership
- Privately Held (backing)
D3 Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in D3 Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on D3 Bio in its N-PORT filings yet. We sweep new filings monthly.